title: Resveratrol attenuates the progress of liver fibrosis via the Akt/nuclear factor-κB pathways.
abstract: Liver fibrosis is a wound-healing response to chronic liver injury that results in the accumulation of extracellular matrix proteins. It eventually leads to cirrhosis of the liver and liver failure, and it is a critical threat to the health and lives of patients with chronic liver diseases. No effective treatment is currently available. Resveratrol is a polyphenol with antioxidant, anti‑cancer and anti‑inflammatory properties. It has been reported that resveratrol prevents liver fibrosis, possibly by inhibiting NF‑κB activation. The present study investigated the mechanisms by which resveratrol prevented liver fibrosis, focusing on the possible involvement of the NF‑κB pathway. Mice with carbon tetrachloride (CCl4)‑induced liver fibrosis were treated with various concentrations of resveratrol. Serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and tumor necrosis factor (TNF)‑α were detected by ELISAs. Expression of α‑smooth muscle actin (α‑SMA), collagen I, inhibitor of NF‑κB (IκB) and NF‑κB were detected by western blot analysis. In addition, the present study examined the effects of resveratrol on the expression of fibrosis markers in LX‑2 cells. Western blot analysis was further used to detect the levels of Akt and phosphorylated Akt, as well as the nuclear levels of IκB, phosphorylated IκB and NF‑κB p65. The expression of α‑SMA in resveratrol‑treated LX‑2 cells was detected by immunofluorescence and flow cytometry, which demonstrated that resveratrol decreased the expression of α‑SMA in LX‑2 cells. Resveratrol also decreased CCl4‑induced upregulation of serum AST, ALT, TNF‑α, α‑SMA and collagen I. Finally, resveratrol prevented the activation of NF‑κB and Akt. The results of the present study therefore indicated that resveratrol attenuates liver fibrosis via the Akt/NF-κB pathways.
authors.affiliation: Department of Infectious Diseases, The Third Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325200, P.R. China.
authors.forename: Hui
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Department of Infectious Diseases, The Third Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325200, P.R. China.
authors.forename: Qingfeng
authors.initials: Q
authors.lastname: Sun
authors.affiliation: Department of Infectious Diseases, The Third Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325200, P.R. China.
authors.forename: Tingyan
authors.initials: T
authors.lastname: Xu
authors.affiliation: Department of Infectious Diseases, The Third Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325200, P.R. China.
authors.forename: Liang
authors.initials: L
authors.lastname: Hong
authors.affiliation: Department of Infectious Diseases, The Third Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325200, P.R. China.
authors.forename: Rongquan
authors.initials: R
authors.lastname: Fu
authors.affiliation: Department of Infectious Diseases, The Third Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325200, P.R. China.
authors.forename: Jinguo
authors.initials: J
authors.lastname: Wu
authors.affiliation: Department of Infectious Diseases, The Third Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325200, P.R. China.
authors.forename: Jiguang
authors.initials: J
authors.lastname: Ding
mesh_terms: D000199:Actins / Q000378:metabolism; D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D002460:Cell Line; D004195:Disease Models, Animal; D018450:Disease Progression; D004789:Enzyme Activation / Q000187:drug effects; D006801:Humans; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology*; D008297:Male; D008810:Mice, Inbred C57BL; D016328:NF-kappa B / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism*; D000077185:Resveratrol; D015398:Signal Transduction / Q000187:drug effects; D013267:Stilbenes / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: C541116:ACTA2 protein, human; D000199:Actins; D015415:Biomarkers; D016328:NF-kappa B; D013267:Stilbenes; D051057:Proto-Oncogene Proteins c-akt; D000077185:Resveratrol